| Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line … D Rodriguez-Abreu, ML Johnson, MA Hussein, M Cobo, AJ Patel, ... Journal of Clinical Oncology 38 (15_suppl), 9503-9503, 2020 | 250 | 2020 |
| Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up … BC Cho, DR Abreu, M Hussein, M Cobo, AJ Patel, N Secen, KH Lee, ... The Lancet Oncology 23 (6), 781-792, 2022 | 196 | 2022 |
| Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer NS Patil, BY Nabet, S Müller, H Koeppen, W Zou, J Giltnane, A Au-Yeung, ... Cancer cell 40 (3), 289-300. e4, 2022 | 172 | 2022 |
| Accessory molecules for MHC class II peptide loading R Busch, RC Doebele, NS Patil, A Pashine, ED Mellins Current opinion in immunology 12 (1), 99-106, 2000 | 154 | 2000 |
| Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer TC Harding, L Long, S Palencia, H Zhang, A Sadra, K Hestir, N Patil, ... Science translational medicine 5 (178), 178ra39-178ra39, 2013 | 150 | 2013 |
| NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes A Singh, A Daemen, D Nickles, SM Jeon, O Foreman, K Sudini, F Gnad, ... Clinical Cancer Research 27 (3), 877-888, 2021 | 96 | 2021 |
| Molecular determinants of response to PD-L1 blockade across tumor types R Banchereau, N Leng, O Zill, E Sokol, G Liu, D Pavlick, S Maund, LF Liu, ... Nature communications 12 (1), 3969, 2021 | 95 | 2021 |
| Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade R Banchereau, AS Chitre, A Scherl, TD Wu, NS Patil, P de Almeida, ... Journal for ImmunoTherapy of Cancer 9 (4), 2021 | 84 | 2021 |
| Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles NS Patil, A Pashine, MP Belmares, W Liu, B Kaneshiro, J Rabinowitz, ... The Journal of Immunology 167 (12), 7157-7168, 2001 | 72 | 2001 |
| Relationship between kinetic stability and immunogenicity of HLA‐DR4/peptide complexes FC Hall, JD Rabinowitz, R Busch, KC Visconti, M Belmares, NS Patil, ... European journal of immunology 32 (3), 662-670, 2002 | 66 | 2002 |
| Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma NS Patil, L Righi, H Koeppen, W Zou, S Izzo, F Grosso, R Libener, ... Journal of Thoracic Oncology 13 (1), 124-133, 2018 | 63 | 2018 |
| ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy W Zou, SJ Yaung, F Fuhlbrück, M Ballinger, E Peters, JF Palma, ... JCO Precision Oncology 5, 827-838, 2021 | 38 | 2021 |
| A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer ZJF Assaf, W Zou, AD Fine, MA Socinski, A Young, D Lipson, JF Freidin, ... Nature Medicine 29 (4), 859-868, 2023 | 36 | 2023 |
| Characterization of HLA DR3/DQ2 transgenic mice: a potential humanized animal model for autoimmune disease studies D Chen, R Ueda, F Harding, N Patil, Y Mao, C Kurahara, G Platenburg, ... European journal of immunology 33 (1), 172-182, 2003 | 30 | 2003 |
| Autoantigenic HCgp39 epitopes are presented by the HLA-DM-dependent presentation pathway in human B cells NS Patil, FC Hall, S Drover, DR Spurrell, E Bos, AP Cope, G Sonderstrup, ... The Journal of Immunology 166 (1), 33-41, 2001 | 29 | 2001 |
| A developmentally regulated deletion element with long terminal repeats has cis-acting sequences in the flanking DNA NS Patil, KM Karrer Nucleic Acids Research 28 (6), 1465-1472, 2000 | 29 | 2000 |
| DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II‐associated invariant chain peptides via multiple mechanisms CH Rinderknecht, S Roh, A Pashine, MP Belmares, NS Patil, N Lu, ... Immunology 131 (1), 18-32, 2010 | 28 | 2010 |
| Alternate Junctions and Microheterogeneity of Tlr1, a Developmentally Regulated DNA Rearrangement in Tetrahymena thermophila NS Patil, PM Hempen, RA Udani, KM Karrer Journal of Eukaryotic Microbiology 44 (5), 518-522, 1997 | 27 | 1997 |
| Clonal hematopoiesis in late-stage non–small-cell lung cancer and its impact on targeted panel next-generation sequencing SJ Yaung, F Fuhlbrück, M Peterson, W Zou, JF Palma, NS Patil, Y Jiang JCO precision oncology 4, 1271-1279, 2020 | 24 | 2020 |
| LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab+ atezolizumab (TA … BC Cho, D Rodriguez-Abreu, M Hussein, M Cobo, A Patel, N Secen, ... Annals of Oncology 32, S1428, 2021 | 23 | 2021 |
